Home > Annual Financials > MANKIND PHARMA

MANKIND PHARMA Financial Statement Analysis
[BOM: 543904|NSE : MANKIND]

The Revenues of MANKIND PHARMA have increased by 12.44% YoY .
The Earnings Per Share (EPS) of MANKIND PHARMA has increased by 49.22 % YoY.
REVENUES
OPERATING MARGIN
PROFIT AFTER TAX
EPS
ROCE

MANKIND PHARMA Last 5 Annual Financial Results
[BOM: 543904|NSE : MANKIND]

ConsolidatedMar2024
Mar2023
Mar2022
Mar2021
Mar2020
Revenues ₹8,749 Cr₹7,782 Cr₹621 Cr₹58,719 Cr₹4,980 Cr
Expenses ₹6,848 Cr₹5,791 Cr₹457 Cr₹44,272 Cr₹4,055 Cr
Operating Profit (Excl OI) ₹1,902 Cr₹1,991 Cr₹165 Cr₹14,447 Cr₹925 Cr
Other Income ₹129 Cr₹196 Cr₹17 Cr₹1,038 Cr₹53 Cr
Interest ₹46 Cr₹60 Cr₹2.12 Cr₹232 Cr₹44 Cr
Depreciation ₹326 Cr₹167 Cr₹12 Cr₹991 Cr₹69 Cr
Profit Before Tax ₹1,671 Cr₹1,975 Cr₹169 Cr₹14,377 Cr₹875 Cr
Profit After Tax ₹1,310 Cr₹1,453 Cr₹129 Cr₹10,561 Cr₹610 Cr
Consolidated Net Profit ₹1,282 Cr₹1,433 Cr₹127 Cr₹10,304 Cr₹579 Cr
Earnings Per Share (Rs)₹47.75₹32.00₹35.78₹31.59₹25.72
PAT Margin (%)18.0614.3818.0020.0017.31
ROE(%)23.1519.2726.7231.5133.48
ROCE(%)28.3823.4933.9639.9743.57
Total Debt/Equity(x)0.020.020.140.050.04

Key Financials

Market Cap : ₹ 98,473.2 Cr
Revenue (TTM) : ₹ 11,641.0 Cr
Net Profit(TTM) : ₹ 2,050.7 Cr
EPS (TTM) : ₹ 49.7
P/E (TTM) : 48.0

Industry Peers & Returns1W1M1Y
MANKIND PHARMA -1.4% -6.9% 5.9%
SUN PHARMACEUTICAL INDUSTRIES 0.5% -3.4% 13.4%
CIPLA 2.2% 3.9% 2.3%
DR REDDYS LABORATORIES -1.5% -7% -5%
ZYDUS LIFESCIENCES -2.3% -7.4% 3.7%
DIVIS LABORATORIES -2.2% 0.3% 58.8%
TORRENT PHARMACEUTICALS -0.6% -3.5% 16.5%
LUPIN -0.6% -4.3% 25%
AUROBINDO PHARMA 1.7% -1.9% 13.2%


MANKIND PHARMA Revenues
[BOM: 543904|NSE : MANKIND]

Y-o-Y

12.44 %

5 Yr CAGR

15.13 %

Years Revenues % Change
Mar2024 ₹8,749 Cr
12.44
Mar2023 ₹7,782 Cr
1,152.18
Mar2022 ₹621 Cr
-98.94
Mar2021 ₹58,719 Cr
1,079.10
Mar2020 ₹4,980 Cr -


MANKIND PHARMA Operating Profit
[BOM: 543904|NSE : MANKIND]

Y-o-Y

-4.45 %

5 Yr CAGR

19.75 %

Years Operating Profit % Change
Mar2024 ₹1,902 Cr
-4.45
Mar2023 ₹1,991 Cr
1,107.04
Mar2022 ₹165 Cr
-98.86
Mar2021 ₹14,447 Cr
1,461.81
Mar2020 ₹925 Cr -

Operating Margins
Y-o-Y

-15.01 %

5 Yr CAGR

4.02 %

Years Operating Margin% % Change
Mar2024 21.74%
-15.01
Mar2023 25.58%
-3.62
Mar2022 26.54%
7.89
Mar2021 24.6%
32.47
Mar2020 18.57% -

MANKIND PHARMA Profit After Tax
[BOM: 543904|NSE : MANKIND]

Y-o-Y

-10.58 %

5 Yr CAGR

22.01 %

Years Profit After Tax % Change
Mar2024 ₹1,282 Cr
-10.58
Mar2023 ₹1,433 Cr
1,032.80
Mar2022 ₹127 Cr
-98.77
Mar2021 ₹10,304 Cr
1,681.10
Mar2020 ₹579 Cr -

PAT Margins
Y-o-Y

25.59 %

5 Yr CAGR

1.07 %

Years PAT Margin(%) % Change
Mar2024 18.06 %
25.59
Mar2023 14.38 %
-20.11
Mar2022 18 %
-10.00
Mar2021 20 %
15.54
Mar2020 17.31 % -

MANKIND PHARMA Earnings Per Share (EPS)
[BOM: 543904|NSE : MANKIND]

Y-o-Y

49.22 %

5 Yr CAGR

16.73 %

Years EPS % Change
Mar2024 ₹48
49.22
Mar2023 ₹32
-10.56
Mar2022 ₹36
13.26
Mar2021 ₹32
22.82
Mar2020 ₹26 -

MANKIND PHARMA Return on Capital Employed (ROCE)
[BOM: 543904|NSE : MANKIND]

Y-o-Y

20.82 %

5 Yr CAGR

-10.16 %

Years ROCE % Change
Mar2024 28.38%
20.82
Mar2023 23.49%
-30.83
Mar2022 33.96%
-15.04
Mar2021 39.97%
-8.26
Mar2020 43.57% -

MANKIND PHARMA Share Price vs Sensex

Current Share Price : ₹2,386.7
Current MarketCap: ₹ 98,473.2 Cr
Updated EOD on :Feb 18,2025

Share Price Returns(%) 1 Week 1 Month 1 Year
MANKIND PHARMA

-1.4%

-6.9%

5.9%

SENSEX

-0.4%

-1.4%

5.4%

MANKIND PHARMA related INDICES

BSE Indices1W1M1Y
S&P BSE LARGECAP -0.8% -3.1% 3.4%
S&P BSE 100 LARGECAP TMC -0.9% -3.1% 3.4%
S&P BSE 200 -1.1% -4% 3.6%
S&P BSE LARGE MIDCAP -1.1% -4.2% 2.9%
S&P BSE 250 LARGEMIDCAP -1.2% -4.3% 3.2%
NSE Indices1W1M1Y
NIFTY 200 -1.1% -4.1% 3.7%
NIFTY PHARMA -1.3% -5.5% 12.9%
NIFTY LARGE MIDCAP 250 -1.6% -6.3% 3.5%
NIFTY 500 -1.6% -5.5% 2.9%
NIFTY FREE MIDCAP 100 -2.2% -9.7% 1.9%

You may also like the below Video Courses


FAQ about MANKIND PHARMA Financials


How the annual revenues of MANKIND PHARMA have changed ?

The Revenues of MANKIND PHARMA have increased by 12.44% YoY .

How the Earnings per Share (EPS) of MANKIND PHARMA have changed?

The Earnings Per Share (EPS) of MANKIND PHARMA has increased by 49.22 % YoY .